Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors
Gilead Sciences offers a 3.98% dividend yield backed by strong profitability and a solid track record, meeting key quality, health, and income criteria.
ChartMill5 saat önceGILD
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
Yahoo5 saat önceGILD
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
YahoodünGILD
Is Gilead Sciences Stock Outperforming the S&P 500?
Gilead Sciences has rallied the S&P 500 Index over the past year, and analysts remain highly bullish about the stock’s growth prospects.
YahoodünGILD
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?
Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Yahooevvelsi günGILD
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Yahoo3 gün önceGILD
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.
Yahoo3 gün önceGILD
3 Unpopular Stocks with Open Questions
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Yahoo4 gün önceGILD
FDA Approves Gilead's New Single Tablet HIV Regimen
The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologically suppressed adults treating HIV.
Benzinga4 gün önceGILD
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
Yahoo7 gün önceGILD
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
Yahoo7 gün önceGILD
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Benzinga10 gün önceGILD
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 15.54%. Currently, Gilead Sciences has a market capitalization of
Benzinga10 gün önceGILD
Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the
Benzinga11 gün önceGILD
Making Drugs With AI: Biopharma Giants Gear Up For New Arena
The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development.
Yahoo14 gün önceGILD
Does Gilead (GILD) Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
In August 2026, Nucleai announced an ongoing translational research collaboration with Gilead Sciences, using AI-powered tissue analytics to support Gilead's global antibody-drug conjugate clinical development programs across multiple oncology indications. The partnership highlights how integrating AI-native computational pathology with clinical outcomes may help standardize biomarker assessment and refine precision medicine efforts in Gilead's oncology portfolio. Next, we'll examine how...
Yahoo15 gün önceGILD
Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022
These stocks can be safe-haven investments to hide out in amid market turmoil.
Yahoo15 gün önceGILD
Biotech Stocks Are Booming. What This Top Fund Is Buying Now.
Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%
Yahoo16 gün önceGILD
HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation
Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN™ AI as a globally recognized healthcare AI platformThe broader 2026 International Prix Galien nominee field includes innovations from many of the world's leading pharmaceutical, biotechnology and medical technology companies, including AstraZeneca, Merck & Co. (MSD), Johnson & Johnson, Pfizer, Sanofi, Regeneron, Roche, Novo...
Yahoo16 gün önceGILD
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
Yahoo16 gün önceGILD
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.
Yahoo17 gün önceGILD
Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
Dr. Charuworn’s extensive immunology drug development experience will help accelerate the clinical development of Coultreon’s first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Prista Charuworn, MD, as Chief Medical Officer. Dr. Charuworn completed fellowships in gastroenterology and transplant hepatology at Stanford and has extensive
Yahoo17 gün önceGILD
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
Assembly Biosciences' key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC. Read why ASMB stock is a Buy.
SeekingAlpha19 gün önceGILD
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
A U.S. appeals court has ruled in favor of Gilead Sciences against companies known as alternative funding programs that import medicines from overseas.
CNBC21 gün önceGILD
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 – – Cash runway projected into 2029, including first $75 million Gilead collaboration extension p
Yahoo21 gün önceGILD
Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run
Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the cheap side rather than pointing to an obvious premium. With that backdrop, investors are weighing whether the recent share price around US$135.87 already reflects the key drivers that have supported the move. A 126.6% return over 5 years suggests Gilead Sciences has rewarded long term holders, so the question is how much of that progress is now priced into the...
Yahoo21 gün önceGILD
Why Gilead Sciences (GILD) Is Back In The Spotlight
Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder returns are above 90%...
Yahoo22 gün önceGILD
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management credited commercial execution and new product launches—including Trodelvy in breast cancer and Livdelzi in liver disease—for boosting results. CEO Daniel O’Day highlighted, “Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time,” underscoring the im
Yahoo22 gün önceGILD
Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics
Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses on translational research to speed up biomarker discovery and support precision oncology development. The AI tools are intended to help standardize and accelerate analysis of tumor samples across Gilead’s oncology pipeline. Gilead is not the only company leaning into AI to reshape drug discovery and development, so...
Yahoo22 gün önceGILD
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
Yahoo23 gün önceGILD
KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’
Joshua Brown chose Snowflake Inc., while Rob Sechan picked KLA Corp and Brian Belski recommended Gilead Sciences. Joseph Terranova went for Airbnb.
Benzinga23 gün önceGILD
